At the conclusion of this activity, participants will be able to:
  • Analyze the main signaling pathways and key mechanisms in DNA damage repair and how deficiencies in these pathways can lead to tumor proliferation and growth.
  • Explore evolving data regarding the efficacy and adverse event profiles of PARP inhibitors currently approved and in clinical development for patients with ovarian and breast cancers.
  • Appraise the importance of recommended genetic testing and counseling in patients with possible deleterious mutations in the DNA damage response pathway and its implications on patient treatment and management.
  • Using a case-based approach, discuss challenging questions regarding PARP inhibitors and examine ways that members of the oncology care team can optimize therapy, enhance safety, anticipate adverse effects, and improve adherence.